Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis and Novozymes in antibiotic development deal

This article was originally published in Scrip

Executive Summary

Sanofi-Aventis and Novozymes have struck a global licensing agreement to develop and market a potential new antibiotic. The two firms will develop plectasin NZ2114, a drug candidate developed by Novozymes for the treatment of severe infections, such as pneumonia, septicaemia and complicated skin and soft tissue infections. Dr Marc Cluzel, senior vice-president of R&D at Sanofi-Aventis, says that the candidate, from a novel class of antimicrobials, is potentially more active against resistant bacteria than currently available treatments. It is a variant of plectasin, a defensin-type peptide antibiotic, which is active against resistant and sensitive Gram-positive bacteria such as Staphylococci and Streptococci. The French company has an exclusive worldwide licence for the development, registration and commercialisation of the drug. Plectasin NZ2114 is the first drug candidate that Novozymes has outlicensed for further preclinical and clinical development, it says. Financial terms were not disclosed.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts